PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30099761-0	2019	Upregulation of C/EBPbeta and TSC2 by an HDAC inhibitor CG200745 protects heart from DOCA-induced hypertrophy.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	56-64	CCAAT/enhancer binding protein beta	Rattus norvegicus	16-25	
30099761-5	2019	We hypothesized that an HDAC inhibitor, CG200745 (CG), ameliorates cardiac hypertrophy through the inhibition of mTORC1 signaling by upregulating of the CCAAT/enhancer-binding protein-beta (C/EBP-beta)/TSC2 pathway.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	40-48	CCAAT/enhancer binding protein beta	Rattus norvegicus	153-188	
30099761-5	2019	We hypothesized that an HDAC inhibitor, CG200745 (CG), ameliorates cardiac hypertrophy through the inhibition of mTORC1 signaling by upregulating of the CCAAT/enhancer-binding protein-beta (C/EBP-beta)/TSC2 pathway.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	40-48	CCAAT/enhancer binding protein beta	Rattus norvegicus	190-200	
30099761-5	2019	We hypothesized that an HDAC inhibitor, CG200745 (CG), ameliorates cardiac hypertrophy through the inhibition of mTORC1 signaling by upregulating of the CCAAT/enhancer-binding protein-beta (C/EBP-beta)/TSC2 pathway.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	40-42	CCAAT/enhancer binding protein beta	Rattus norvegicus	153-188	
30099761-5	2019	We hypothesized that an HDAC inhibitor, CG200745 (CG), ameliorates cardiac hypertrophy through the inhibition of mTORC1 signaling by upregulating of the CCAAT/enhancer-binding protein-beta (C/EBP-beta)/TSC2 pathway.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	40-42	CCAAT/enhancer binding protein beta	Rattus norvegicus	190-200	
30099761-12	2019	In addition, CG treated rats showed an increased in the expression and acetylation of C/EBP-beta, owing to the increase in the recruitment of C/EBP-beta and Pol II at Tsc2 gene promoter.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	13-15	CCAAT/enhancer binding protein beta	Rattus norvegicus	86-96	
30099761-12	2019	In addition, CG treated rats showed an increased in the expression and acetylation of C/EBP-beta, owing to the increase in the recruitment of C/EBP-beta and Pol II at Tsc2 gene promoter.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	13-15	CCAAT/enhancer binding protein beta	Rattus norvegicus	142-152	
30099761-13	2019	Thus, CG ameliorates cardiac hypertrophy through the inhibition of mTORC1 signaling via upregulation of the C/EBP-beta/TSC2 pathway in DOCA-induced hypertensive rats.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	6-8	CCAAT/enhancer binding protein beta	Rattus norvegicus	108-118